Phase 2, Randomized, Open-Label Study comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects with Newly Diagnosed Multiple Myeloma Eligible for High dose chemo

Administered By

Awarded By

Contributors

Start/End

  • October 11, 2017 - June 30, 2022